Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
P Zhong, H Zeng, M Huang, W Fu, Z Chen - Endocrine, 2022 - Springer
Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …
semaglutide among adults with overweight or obesity. Methods We searched multiple …
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including …
W Qin, J Yang, C Deng, Q Ruan… - Diabetes, Obesity and …, 2024 - Wiley Online Library
Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
Once-weekly semaglutide in adults with overweight or obesity
JPH Wilding, RL Batterham, S Calanna… - … England Journal of …, 2021 - Mass Medical Soc
Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
[HTML][HTML] Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis
HC Tan, OA Dampil, MM Marquez - Journal of the ASEAN …, 2022 - ncbi.nlm.nih.gov
Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …
documented, but its clinical utility in treating obesity among patients without diabetes is less …
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled …
X Gao, X Hua, X Wang, W Xu, Y Zhang… - Frontiers in …, 2022 - frontiersin.org
Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …
conventional anti-obesity drug systematically in obese or overweight patients without …
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis
N Arastu, O Cummins, W Uribe, EC Nemec - International journal of …, 2022 - Springer
Background Research on semaglutide's effect on weight loss has been largely focused on
Type 2 Diabetics. No meta-analyses of semaglutide's efficacy in non-diabetic individuals …
Type 2 Diabetics. No meta-analyses of semaglutide's efficacy in non-diabetic individuals …
Semaglutide 2.4 Mg for the management of overweight and obesity: systematic literature review and meta-analysis
I Smith, E Hardy, S Mitchell, S Batson - … , Metabolic Syndrome and …, 2022 - Taylor & Francis
Purpose Semaglutide has demonstrated safe and effective weight loss for overweight and
obesity, including participants with concomitant type 2 diabetes mellitus (T2DM), in …
obesity, including participants with concomitant type 2 diabetes mellitus (T2DM), in …
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
D Rubino, N Abrahamsson, M Davies, D Hesse… - Jama, 2021 - jamanetwork.com
Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …
Clinical review of subcutaneous semaglutide for obesity
A Phillips, JN Clements - Journal of clinical pharmacy and …, 2022 - Wiley Online Library
What is known and objective The purpose of this review paper is to review the efficacy and
safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 …
safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 …
Semaglutide for the treatment of overweight and obesity: a review
Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …
substantial morbidity, mortality and health care burden. Pharmacological treatments for …